+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin cardiomyopathy? A potential role for Co-Enzyme Q10 therapy for statin-induced changes in diastolic LV performance: description of a clinical protocol

Statin cardiomyopathy? A potential role for Co-Enzyme Q10 therapy for statin-induced changes in diastolic LV performance: description of a clinical protocol

Biofactors 18(1-4): 125-127

Lipid-lowering statins are thought to have a favorable safety profile. Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting step of mevalonate synthesis. Mevalonate is the substrate for further synthesis of cholesterol and Co Enzyme Q10 (CoQ10). CoQ10 plays an important role during oxidative phosphorylation in the myocardial cell. Since myocardial diastolic function is a highly ATP dependent, we reasoned that early changes of diastolic function may be an early marker of ventricular dysfunction. Methods: Patients who are to commence on statin therapy will be enrolled in the trial. Baseline measurements of plasma CoQ10, total cholesterol, LDL, HDL, CoQ10/LDL ratio, peak E, peak A velocities, E/A ratio, deceleration time, isovolumetric relaxation time, color M-mode propagation velocity will be performed and patients will then begin to take Oral atorvastatin (Lipitor, Parke-Davis) 20 mg daily for three to six months. All baseline measurement will be repeated after 3 to 6 months of statin therapy. Those patients demonstrating >1 measurement of diastolic LV function that worsened during the 3 to 6 months of statin therapy will be supplemented with CoQ10 300 mg. daily for 3 months. A followup echocardiogram and blood CoQ10 level will be measured in patients who received CoQ10 supplementation. Results: Statistical analysis will be performed using the paired t test to compare coenzyme levels and echocardiographic indices at baseline and after treatment and after supplementation.

(PDF emailed within 0-6 h: $19.90)

Accession: 012581484

Download citation: RISBibTeXText

PMID: 14695927

DOI: 10.1002/biof.5520180214

Related references

Insulin resistance due to statin therapy: a potential contributor to the negation of statin-induced beneficial effects on cardiac remodelling in heart failure?. International Journal of Cardiology 146(3): 417, 2011

A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. Journal of Cardiology 60(1): 12-17, 2013

A peri-operative statin update for non-cardiac surgery. Part I: The effects of statin therapy on atherosclerotic disease and lessons learnt from statin therapy in medical (non-surgical) patients. Anaesthesia 63(1): 52-64, 2007

Rechallenging Statin Therapy in Veterans With Statin-Induced Myopathy Post Vitamin D Replenishment. Journal of Pharmacy Practice 30(5): 521-527, 2016

Statin therapy and reductions in low-density lipoprotein cholesterol: Initial clinical data on the potent new statin rosuvastatin. American Journal of Cardiology 87(5A): 33B-36B, March 8, 2001

Tu-W27:4 Comparative lipid effects of combination therapy with a statin and extended-release niacin versus statin plus ezetimibe versus a statin alone. Atherosclerosis Supplements 7(3): 174-175, 2006

Mislabeling of Study Design and Overstatement of Findings in "Rechallenging Statin Therapy in Veterans With Statin-Induced Myopathy Post Vitamin D Replenishment". Journal of Pharmacy Practice 30(3): 385, 2018

Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines. Clinical Cardiology 37(11): 653-659, 2015

Clinical outcome of statin plus ezetimibe versus high-intensity statin therapy in patients with acute myocardial infarction propensity-score matching analysis. International Journal of Cardiology 225: 50-59, 2016

Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes, Obesity and Metabolism 13(7): 615-628, 2011

RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale. Lipids in Health and Disease 12: 142, 2014

Statin therapy/lipid lowering therapy among Indian adults with first acute coronary event: The dyslipidemia Residual and Mixed Abnormalities IN spite of Statin therapy (REMAINS) study. Indian Heart Journal 68(5): 646-654, 2016

Trends in Utilization of Statin Therapy and Contraindicated Statin Use in HIV--Infected Adults Treated With Antiretroviral Therapy From 2007 Through 2015. Journal of the American Heart Association 7(24): E010345-E010345, 2018

Association between statin use and lipid status in quality improvement initiatives: statin use, a potential surrogate?. Quality in Primary Care 20(6): 401-407, 2013

Interindividual differences in the response to statin therapy and gene polymorphisms related to myopathy during statin therapy. Giornale Italiano di Cardiologia 12(3): 182-185, 2011